We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Proposes Using Fibrinogen as Biomarker in COPD Clinical Trials
EMA Proposes Using Fibrinogen as Biomarker in COPD Clinical Trials
The European Medicines Agency published a draft proposal to accept measurements of fibrinogen as a biomarker to identify chronic obstructive pulmonary disease patients for inclusion in clinical trials.